<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371071</url>
  </required_header>
  <id_info>
    <org_study_id>EK1/2011</org_study_id>
    <nct_id>NCT01371071</nct_id>
  </id_info>
  <brief_title>Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis</brief_title>
  <acronym>CIS-COHORT</acronym>
  <official_title>Clinically Isolated Syndrome and Newly Diagnosed Multiple Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational Study (Berlin CIS-COHORT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A majority of patients with multiple sclerosis initially presents with a single demyelinating
      event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically
      isolated syndrome (CIS). Not all patients with CIS get a relapse and develop multiple
      sclerosis but in those patients who do, irreversible damage of the central nervous system,
      e.g. axonal damage, is already detectable in that early stage of disease. Early initiation of
      immunomodulatory therapy is crucial for patients with clinically isolated syndrome who are at
      high risk for the development of multiple sclerosis. Vice versa identification of low risk
      patients could help to avoid an unnecessary therapy. In this prospective observational study
      we want to follow up patients with CIS and early multiple sclerosis over a period of four
      years and obtain clinical, laboratory and MRI - data in order to identify risk factors for
      relapses, prognostic factors and therapy response markers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time (in days) until relapse during the observation period of four years</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI - parameters: number and volume of T2 and gadolinium enhancing lesions, analysis of lesion patterns (spinal und cerebral MRI)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers: RNA, microRNA, DNA, proteins, enzymes, autoantibodies, antiviral antibodies, virus DNA, Vitamin D and lipids in serum, plasma, peripheral cells, urine, saliva and CSF</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography (OCT): thickness of the retinal nerve fibre layer (RNFL) or total macular volume (TMV)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis, MS</condition>
  <condition>Clinically Isolated Syndrome</condition>
  <arm_group>
    <arm_group_label>CIS or early relapsing-remitting MS</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples (serum and plasma, with DNA), urine, saliva, CSF (if routine lumbar puncture
      was performed, no additional lumbar punctures for the study)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruted at neurological outpatient clinics and neurologcial clinics of
        the charité and neurologists' medical practices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  signed informed consent

          -  clinically isolated syndrome within the last 6 months

          -  diagnosis of multiple sclerosis within the last two years

        Exclusion Criteria:

          -  eye disease that could interfere with OCT (e.g. glaucoma, diabetic retinopathy)

          -  secondary progressive multiple sclerosis

          -  pregnancy

          -  contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium

          -  alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite - Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klemens Ruprecht, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Bellmann-Strobl, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Friedemann Paul, Prof.</last_name>
    <phone>0049 30 450</phone>
    <phone_ext>539040</phone_ext>
    <email>friedemann.paul@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klemens Ruprecht, Dr.</last_name>
    <phone>0049 30 450</phone>
    <phone_ext>560374</phone_ext>
    <email>klemens.ruprecht@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klemens Ruprecht, Dr.</last_name>
      <phone>0049 30 450</phone>
      <phone_ext>560 374</phone_ext>
      <email>klemens.ruprecht@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedemann Paul, Prof.</last_name>
      <phone>0049 30 450</phone>
      <phone_ext>539040</phone_ext>
      <email>friedemann.paul@charite.de</email>
    </contact>
    <investigator>
      <last_name>Seija Lehnardt, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neurocure.de</url>
    <description>Homepage of the NeuroCure Clinical Research Center</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Friedemann Paul, MD; Klemens Ruprecht, MD; Judith Bellmann-Strobl, MD</name_title>
    <organization>Charité - Universiätsmedizin Berlin</organization>
  </responsible_party>
  <keyword>Clinically isolated syndrome (CIS)</keyword>
  <keyword>Multiple sclerosis (MS)</keyword>
  <keyword>Immunomodulatory therapy</keyword>
  <keyword>Prognostic markers</keyword>
  <keyword>MRI</keyword>
  <keyword>OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

